<DOC>
	<DOCNO>NCT00125593</DOCNO>
	<brief_summary>The chief aim SHARP determine whether lower blood LDL cholesterol simvastatin ( 20mg ) plus ezetimibe ( 10mg ) daily could safely reduce risk coronary heart disease , non-hemorrhagic stroke need revascularization procedure patient chronic kidney disease ( CKD ) . It also aim assess whether lower LDL cholesterol reduce rate loss renal function people CKD commence dialysis treatment .</brief_summary>
	<brief_title>Study Heart Renal Protection</brief_title>
	<detailed_description>The SHARP ( Study Heart Renal Protection ) double-blind placebo-controlled trial aim assess safety efficacy reduce LDL cholesterol 9,000 patient chronic kidney disease ( 3,000 dialysis randomization ) . Patients randomly assign simvastatin 20 mg plus ezetimibe 10 mg daily versus match placebo ( subset patient previously receive simvastatin 20mg randomly re-assigned receive simvastatin 20mg plus ezetimibe 10mg placebo one year ) . Details SHARP trial design method report previously ( reference : Am Heart J 2010 ; 160:785-94. ) . SHARP overseen independent Steering Committee include nephrologists , cardiologist , clinical trialists , statistician , 2 non-voting observer main funder ( Merck/Schering-Plough Pharmaceuticals ) . The independent sponsor University Oxford , trial fund Merck/Schering-Plough Pharmaceuticals , Australian National Health Medical Research Council , British Heart Foundation UK Medical Research Council . In October 2009 , Steering Committee decide ( blind effect study treatment clinical outcome ) change original protocol-specified primary outcome revise key outcome major atherosclerotic event , define combination non-fatal myocardial infarction , coronary death , ischemic stroke , revascularization procedure ( i.e . exclusion non-coronary cardiac death stroke confirm hemorrhagic original major vascular event outcome ) . These change describe revised statistical analysis plan SHARP ( reference : Am Heart J 2010 ; 160:785-94. ) . Accordingly , chief emphasis publish result ( reference : Lancet 2011 ; 377:2181-92 ) revise pre-specified key outcome first major atherosclerotic event .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<criteria>History chronic kidney disease ( CKD ) : either patient predialysis ( plasma serum creatinine great equal 150 micromol/l [ great equal 1.7 mg/dl ] men , great equal 130 micromol/l [ great equal 1.5 mg/dl ] woman ) ; patient dialysis ( hemodialysis peritoneal dialysis ) Men woman age great equal 40 year Definite history myocardial infarction coronary revascularization procedure Functioning renal transplant , live donorrelated transplant plan Less 2 month since presentation acute uraemic emergency ( could enter later , appropriate ) Definite history chronic liver disease , abnormal liver function ( i.e . alanine aminotransferase [ ALT ] great 1.5 x upper limit normal [ ULN ] , ALT available , aspartate aminotransferase [ AST ] great 1.5 x ULN ) . ( Note : Patients history hepatitis eligible provide limit exceed . ) Evidence active inflammatory muscle disease ( e.g . dermatomyositis , polymyositis ) , creatine kinase ( CK ) great 3 x ULN Definite previous adverse reaction statin ezetimibe Concurrent treatment contraindicate drug . ( Note : Patients temporarily take drug could rescreened participation study discontinue , appropriate . ) These contraindicate drug include : HMGCoA reductase inhibitor ( `` statin '' ) ; fibric acid derivative ( `` fibrate '' ) ; nicotinic acid ; macrolide antibiotic ( erythromycin , clarithromycin ) ; systemic use imidazole triazole antifungal ( e.g . itraconazole , ketoconazole ) ; proteaseinhibitors ( e.g . antiretroviral drug HIV infection ) ; nefazodone ; ciclosporin Childbearing potential ( i.e . premenopausal woman use reliable method contraception ) Known poorly compliant clinic visit prescribe medication Medical history might limit individual 's ability take trial treatment duration study ( e.g . severe respiratory disease , history cancer nonmelanoma skin cancer , recent history alcohol substance misuse )</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Kidney Disease , Chronic</keyword>
	<keyword>LDL cholesterol</keyword>
	<keyword>simvastatin</keyword>
	<keyword>ezetimibe</keyword>
	<keyword>cardiovascular disease</keyword>
	<keyword>atherosclerosis</keyword>
</DOC>